| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35385c461df189cd34d08d2b9237603f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6873 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5215b82e7cc12c613cf8b58a85bd709d |
| publicationDate |
2020-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3723763-A2 |
| titleOfInvention |
Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof |
| abstract |
The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizing a cancer with such combinations. Also provided are pharmaceutical compositions including such combinations. |
| priorityDate |
2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |